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a  b  s  t  r  a  c  t
This study  assessed  the  human  epidermal  growth  factor  receptor-2  (HER2)  protein  expres-
sion in urothelial  bladder  carcinoma  and  its relationship  with  p53  and  p63 expression.
In  151  patients,  parafﬁn-embedded  tissues  of transurethral  resection  or cystectomy  were
evaluated by  immunohistochemistry  (IHC),  using  antibodies  against  HER2,  p53 and  p63.
HER2 overexpression  (score  3+),  p53 overexpression  and  decreased  expression  of  p63  were
detected in  14 (9.3%),  48  (31.8%)  and  58  (38.4%)  tumors,  respectively.  HER2  overexpress-
ion,  p53  overexpression  and  decreased  expression  of p63  were  associated  with  high  tumor
grade (p  =  0.0002,  p =  0.0002  and  p =  0.046,  respectively)  and advanced  TNM  stage  (p = 0.017,
p = 0.012  and  p  =  0.001,  respectively)  of urothelial  bladder  carcinoma.  In  univariate  analy-
sis  HER2  overexpression  was  signiﬁcantly  associated  with decreased  expression  of  p63
(p =  0.037).  In multivariate  analysis,  only  tumor  grade  was  correlated  with  HER2  over-
expression  (p = 0.006).  In this  study,  HER2  is  overexpressed  in  9.3%  of  urothelial  bladder
carcinomas.  HER2  overexpression  was strongly  correlated  with  tumor  grade  but not  with
TNM stage,  p53  and  p63.  The  development  of  target  therapies  using  anti-HER2  and the
identiﬁcation  of patients  which  who  beneﬁt  from  those  therapies  need  further  studies.
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grade and TNM stage are two independent factors which
determine the treatment strategy. The human epidermal
growth factor receptor-2 (HER2) is known to contribute to
physiologic  mechanisms of cell proliferation by an intrin-
sic  tyrosine kinase activity. The assessment of the HER2
status is crucial for the management of breast cancer, for
both  prognosis and prediction of the response to targeted
therapies. In urothelial bladder carcinoma, immunohisto-
chemical HER2 expression varies among different studies,
ranging from 9 to 81% [3–13]. Recently a large multicen-
ter series investigating invasive bladder carcinoma has
shown  HER2 overexpression in 9.2% [12]. Several studies
have  demonstrated that p53 and p63 are two prognostic
Open access under CC BY-NC-ND license.markers for urothelial carcinoma associated to tumor
progression and poor clinical outcome [15–19]. This study
explored whether immunohistochemical HER2 expression
is  related to these two  markers (p53 and p63).
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Table 1
Histopathological characteristics of the bladder tumors.
Number Percentage (%)
Low grade 103 68.2
High grade 48 31.8
pTa + pT1 100 66.2
≥pT2 51 33.8
2. Materials and methods
2.1.  Study population and tissue specimens
A series of 151 tumors from 151 patients (130 men
and 21 women; mean age 65.94 ± 12.8 years, range
26–101 years) diagnosed with primary urothelial car-
cinoma of the urinary bladder was selected from the
Habib Bourguiba Pathology Department ﬁles from 2006
to  2008. Parafﬁn-embedded tissues were obtained after
transurethral resection for bladder tumor or cystectomy.
Histological examination on hematoxylin–eosin (H&E)
stained slides was carried out conﬁrming the diagnosis
urothelial cell carcinoma. The TNM classiﬁcation was used
for  tumor staging and the 2004 WHO  classiﬁcation for
tumor  grading [20,21]. Tumor grade and TNM stage of these
tumors  were summarized in Table 1.
2.2. Immunohistochemistry
Before immunostaining, two pathologists (SC and AK)
reviewed hematoxylin–eosin stained slides from the orig-
inal  parafﬁn-embedded blocks in each case. One section
representing the most invasive areas of each tumor was
selected. Brieﬂy, 4 m-thick sections were cut from each
parafﬁn block, mounted on poly-l-lysinecoated slides,
ﬁxed  in acetone for 10 min, and left to dry overnight at
37 ◦C. Slides were deparafﬁnized in xylene followed by
absolute  ethanol and subsequent rehydration in graded
ethanol. The sections were then pre-treated with 3%
hydrogen peroxide for 10 min  to inactivate endogenous
peroxides and washed in phosphate-buffered saline (PBS)
solution.  Heat-induced antigen retrieval was performed
using epitope retrieval solution (DAKO) at 95 ◦C for 40 min.
After  heating, slides were allowed to cool down to room
temperature and were brieﬂy washed with PBS. Blocking
solution (Protein Block Serum: 0.25% Casein in PBS contain-
ing  Carrier Protein and NaN3; DAKO) was used for 5 min  to
prevent  nonspeciﬁc immunostaining. Immunohistochem-
ical staining was performed using the streptavidin-biotin
peroxidase system. Slides were incubated for 30 min  at
room  temperature with anti-HER2 (clone CB11, Novocas-
tra,  Newcastle upon Tyne, UK; dilution, 1/40), anti-p53
(Clone: DO-7, code: M7001, DAKO; dilution, 1/50) and
anti-p63 (Clone: A4A, code: M7247, DAKO; dilution, 1/40),
then  washed with PBS before applying the biotinylated
secondary antibody (anti-rabbit, DAKO) for 5 min. Sec-
tions  were incubated with the streptavidin-biotin complex
reagent (Universal Quick Kit, DAKO) for 15 min  and
developed with 3,3′-diaminobenzidine tetrahydrochloride
(DAB) for 30 min. Finally, tissues sections were counter-
stained by Mayer’s hematoxylin, dehydrated, and mountedd Ultrastructure 1 (2013) 17–21
(DAKO).  Internal/external, positive/negative controls for
each  antibody were used for validation of the reac-
tions.
2.3. Evaluation of immunohistochemical staining
HER2 positivity was assessed using the ASCO sco-
ring system, evaluating only membranous staining [22].
The  level of HER2 protein expression was  assessed semi-
quantitatively by the intensity and percentage of staining
and  scored on a scale of 0–3+. Only tumors with score 3+
are  categorized as positive. A score of 1+ was deﬁned as
barely  perceptible membrane staining in >10% of cells, a
score  of 2+ was  deﬁned as weak-to-moderate complete
membrane staining present in >10% of tumor cells, and
a  score of 3+ was  deﬁned as strong complete membrane
staining in >30% of tumor cells. A cytoplasmic staining
was  considered nonspeciﬁc. Only nuclear immunostain-
ing for p53 and p63 was  considered positive. Regarding
p53, tumors showing immunoreactivity of more 10% of
tumor  cell nuclei were considered positive (p53 overex-
pression), in accordance with the practice used in previous
studies because it has been shown that accumulation of
p53  protein in 10% or more of the tumor cell nuclei strongly
correlates with mutations in the p53 gene [18,19,23]. For
p63  immunoreactivity, a cut off of 90% was used con-
sidering tumors with immunoreactivity less than 90% of
cell  as decreased expression of p63 and staining of more
than  90% of cells as normal [23]. All ﬁelds of the sec-
tion has been analysed by two  pathologists (S.C. and A.K.)
using  multi viewing microscope. When the results were
different, agreement was reached with careful discus-
sion.
2.4. Statistical analysis
Data  available for statistical evaluation was performed
with Statistical Package for the Social Sciences SPSS
(version 17.0, IBM, Chicago, IL, USA) for windows soft-
ware.  Initially, a descriptive analysis of all collected
variables was performed. The correlation between expres-
sion  of HER2, p53, p63 and tumor grade and TNM
stage were assessed with Fisher’s exact and chi-square
tests. The same tests were used for the correlation
between p53, p63 and HER2 expression. For multivariate
analysis, binary logistic regression was  performed incor-
porating signiﬁcant parameters by the univariate analysis.
All  differences were deemed signiﬁcant at the level of
p  < 0.05.
3. Results
3.1. Expression of HER2 and association with pathologic
characteristics
Strong protein expression (3+) was  observed in 14
of  151 tumors (9.3%) (Fig. 1). An immunohistochemistry
0/1+ score was detected in respectively 55 (36.4%) and 61
(40.4%).  21 cases (13.9%) were scored as 2+. HER2 overex-
pression was signiﬁcantly associated with the tumor grade
(p  = 0.0002) and TNM stage (p = 0.017) (Table 2).
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Table 2
Association of HER2, p53 and p63 immunostaining with histopathological parameters.
HER2 overexpression p-value p53 overexpression p-value Loss p63 expression p-value
+ − + − + −
Low grade 3 (1.9%) 100 (66.2%) 0.0002 23 (15.2%) 80 (52.9%) 0.0002 34 (22.5%) 69 (45.6%) 0.046
High grade 11 (7.2%) 37 (24.5%) 25 (16.5%) 
pTa  + pT1 5 (3.3%) 95 (62.9%) 0.017 25 (16.5%) 
≥pT2 9 (5.9%) 42 (27.8%) 23 (15.2%) 
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In this study, 151 primary urothelial bladder carcino-
mas  from Tunisian population were screened for HER2
expression and its correlation with p53 and p63 expres-
sion. To our knowledge, this is the ﬁrst study to analyseig. 1. Strong and diffuse HER2 immunostaining surrounding the entire
ell membrane (score 3+) (HER2 400×).
.2. Expression of p53 and p63 and association with
athologic characteristics (Table 2)
Overexpression of p53 was observed in 48 of 151
umors (31.8%). Decreased expression of p63 expression
as found in 58 of 151 tumors (38.4%) (Figs. 2 and 3).
53  overexpression and decreased expression of p63 were
orrelated with high tumor grade (p = 0.0002 and 0.046,
espectively) and TNM stage (p = 0.017 and 0.012, respec-
ively) (Table 2).
.3.  Association of HER2 expression with p53 and p63
xpression
In  a statistical analysis of the association between HER2
xpression and p53/p63 expression, HER2 overexpression
as correlated to a decreased expression of p63 (p = 0.037)
ut  not with p53 overexpression (p = 0.350) (Table 3).
able 3
ssociation of immunohistochemical HER2 expression with p53 and p63
xpression.
Her-2 overexpression p-value
+ −
p53 overexpression
+  6 (3.9%) 42 (27.8%) 0.350
−  8 (5.2%) 95 (62.9%)
Decreased p63 expression
+  9 (5.9%) 49 (32.4%) 0.037
−  5 (3.3%) 88 (58.2%)23 (15.2%) 24 (15.8%) 24 (15.8%)
75 (59.6%) 0.012 29 (19.2%) 71 (47%) 0.001
28 (18.5%) 29 (19.2%) 22 (14.5%)
3.4. Multivariate analysis of combined variables
incorporating pathologic characteristics
In a multivariate analysis considering tumor grade,
decreased expression of p63 and TNM stage as co-variables,
HER2 overexpression was  correlated with tumor grade
(p  = 0.006) but not with decreased expression of p63 and
TNM  stage.
4.  DiscussionFig. 2. p53 immunohistochemical expression. (A) diffuse nuclear staining
of tumor cells (p53 200×). (B) p53 immunostaining in less than 10% of
tumor cells (p53 200×).
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Fig. 3. p63 immunohistochemical expression. (A) strong and diffuse
nuclear staining of neoplastic urotlelial cells in low grade tumor (p63
200×). (B) heterogenous immunoreactivity in high grade tumor (p63
200×).
immunohistochemical correlations of Her-2 with p53 and
p63.  HER2 is overexpressed in 9.3% of tumor samples which
is  comparable to rates of 9.2 (tumors 2+ and 3+) and 5.1%
(tumors 3+) reported by Laé et al. [14]. But this rate is lower
than  reported in several previous studies ranging from
21.7%  to 80% [3,4,6–10,12,13]. Several hypotheses could
explain these wide variations, as well as the relatively low
rate  of HER2 overexpression reported in our series. One of
the  major issues is the variability in immunohistochem-
istry assays, related to the heterogeneity between kits,
antibodies, protocols, interpretations of staining or cut-off
values.  Scoring systems are variable and there is no con-
sensus  on the deﬁnition of HER2 overexpression in bladder
carcinoma. Most authors used criteria of Wolff et al.
reported for breast carcinoma (ASCO scoring system) [22].
In  our study only tumors scored 3+ were considered
overexpressing HER2. We  consider that tumors scored 2+
should  not be considered as overexpressing Her-2 with-
out  demonstration of HER2 gene ampliﬁcation by in situ
hybridization technique. In fact, literature data showed
that  the majority of cases scored 2+ are not ampliﬁcated
by in situ hybridisation. In the study of Laé et al., all cases
scored 2+ (n = 42) were negative by ﬂuorescent in situ
hybridization (FISH) technique [14]. Moreover, Caner et al.d Ultrastructure 1 (2013) 17–21
noted  that only 2 among 9 cases were ampliﬁcated by FISH
and  4 among 12 cases were ampliﬁcated by real-time quan-
titative  PCR for HER2 status [4].
P53 overexpression in urothelial carcinoma was
reported in 30.8–60% [24,25]. Some investigators noted a
prognostic  signiﬁcance for p53 staining in both univari-
ate  and multivariate analysis [24,26–28]. Shariat et al. [16]
demonstrate that p53 is the strongest predictor marker of
bladder  carcinoma outcome in patient undergoing radical
cystectomy. In our series p53 was overexpressed in 31.8%
of  tumors and was  correlated to higher tumor grade and
TNM  stage. p63 is a homologue of the p53 tumor suppres-
sor  gene, that encodes multiple proteins that may either
transactivate p53 responsive genes (Tap63) or act as a dom-
inant  negative factor toward p53 (deltaNp63) [19]. p63
is  constitutively expressed in the basal cell compartment
of the stratiﬁed epithelium, including the urothelium, in
which  deltaNp63 is the predominant isoform expressed
[15]. p63 is decreased in most invasive cancers whereas
papillary superﬁcial tumors maintain its p63 expression
[19]. In urothelial carcinoma, decreased deltaNp63 expres-
sion  is associated with more advanced disease and poorer
prognosis [15,17,19,23]. In our series decreased expression
of  p63 was associated with higher grade and TNM stage.
In  our study, HER2 overexpression was correlated with
decreased expression of p63 in univariate analysis. This
correlation was  lost on multivariate analysis. In fact HER2
overexpression was  signiﬁcantly related to tumor grade
but  not with TNM stage and p63 expression.
5. Conclusion
In conclusion, HER2 was overexpressed in 9.3% of
urothelial carcinoma in the current study, and was strongly
correlated with high tumor grade. The development of
target  therapies using anti-HER2 and the identiﬁcation of
patients  who  may  beneﬁt from those therapies need fur-
ther  studies.
Conﬂict of interest
We  have no conﬂict of interest to declare.
References
[1] Curado MP,  Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al.
Cancer  incidence in ﬁve continents. Lyon: IARC Scientiﬁc Publica-
tions; 2007.
[2] Hsairi M,  Fakhfakh R, Ben Abdallah M,  Jlidi R, Sellami A, Zheni S,
et  al. Assessment of cancer incidence in Tunisia 1993–1997. Tunisie
Medicale 2002;80:57–64.
[3] Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky
AI, et al. Human epidermal growth factor receptor 2 expression
status provides independent prognostic information in patients
with urothelial carcinoma of the urinary bladder. BJU International
2010;106:1216–22.
[4] Caner V, Turk NS, Duzcan F, Tufan NL, Kelten EC, Zencir S, et al.
No  strong association between HER-2/neu protein overexpression
and gene ampliﬁcation in high-grade invasive urothelial carcinomas.
Pathology Oncology Research 2008;14:261–6.
[5]  Gandour-Edwards R, Lara Jr PN, Folkins AK, LaSalle JM, Beckett L,
Li  Y, et al. Does HER2/neu expression provide prognostic infor-
mation in patients with advanced urothelial carcinoma? Cancer
2002;95:1009–15.
[6]  Hansel DE, Swain E, Dreicer R, Tubbs RR. HER2 overexpression and
ampliﬁcation in urothelial carcinoma of the bladder is associated
copy an
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[S. Charﬁ et al. / Journal of Micros
with MYC coampliﬁcation in a subset of cases. American Journal of
Clinical  Pathology 2008;130:274–81.
[7] Hussain MH,  MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan
U, Lara Jr PN, et al. Trastuzumab, paclitaxel, carboplatin, and
gemcitabine in advanced human epidermal growth factor receptor-
2/neu-positive urothelial carcinoma: results of a multicenter phase
II  National Cancer Institute trial. Journal of Clinical Oncology
2007;25:2218–24.
[8]  Jalali Nadoushan MR,  Taheri T, Jouian N, Zaeri F. Overexpression
of HER-2/neu oncogene and transitional cell carcinoma of bladder.
Urology Journal 2007;4:151–4.
[9] Matsubara H, Yamada Y, Naruse K, Nakamura K, Aoki S, Taki
T,  et al. Potential for HER-2/neu molecular targeted therapy for
invasive bladder carcinoma: comparative study of immunohisto-
chemistry and ﬂuorescent in situ hybridization. Oncology Reports
2008;19:57–63.
10]  Naruse K, Yamada Y, Nakamura K, Aoki S, Taki T, Zennami K, et al.
Potential of molecular targeted therapy of HER-2 and Cox-2 for inva-
sive  transitional cell carcinoma of the urinary bladder. Oncology
Reports 2010;23:1577–83.
11] Olsson H, Fyhr IM,  Hultman P, Jahnson S. HER2 status in primary stage
T1  urothelial cell carcinoma of the urinary bladder. Scandinavian
Journal of Urology and Nephrology 2012;46:102–7.
12]  Simonetti S, Russo R, Ciancia G, Altieri V, De Rosa G, Insabato L.
Role  of polysomy 17 in transitional cell carcinoma of the bladder:
immunohistochemical study of HER2/neu expression and ﬁsh anal-
ysis  of c-erbB-2 gene and chromosome 17. International Journal of
Surgical  Pathology 2009;17:198–205.
13] Skagias L, Politi E, Karameris A, Sambaziotis D, Archondakis A, Vasou
O,  et al. Prognostic impact of HER2/neu protein in urothelial bladder
cancer. Survival analysis of 80 cases and an overview of almost 20
years’  research. Journal of BUON 2009;14:457–62.
14]  Laé M,  Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A.
Assessing  HER2 gene ampliﬁcation as a potential target for therapy in
invasive  urothelial bladder cancer with a standardized methodology:
results in 1005 patients. Annals of Oncology 2010;21:815–9.
15] Fukushima H, Koga F, Kawakami S, Fujii Y, Yoshida S, Ratovit-
ski E, et al. Loss of DeltaNp63alpha promotes invasion of
urothelial carcinomas via N-cadherin/Src homology and colla-
gen/extracellular signal-regulated kinase pathway. Cancer Research
2009;69:9263–70.
16]  Karni-Schmidt O, Castillo-Martin M,  Shen TH, Gladoun N, Domingo-
Domenech J, Sanchez-Carbayo M,  et al. Distinct expression proﬁles
of  p63 variants during urothelial development and bladder cancer
progression. American Journal of Pathology 2011;178:1350–60.
[d Ultrastructure 1 (2013) 17–21 21
17] Koga F, Kawakami S, Kumagai J, Takizawa T, Ando N, Arai G, et al.
Impaired Delta Np63 expression associates with reduced beta-
catenin and aggressive phenotypes of urothelial neoplasms. British
Journal of Cancer 2003;88:740–7.
18] Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF,
et  al. p53, p21, pRB, and p16 expression predict clinical outcome
in cystectomy with bladder cancer. Journal of Clinical Oncology
2004;22:1014–24.
19] Urist MJ,  Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum
CP, et al. Loss of p63 expression is associated with tumor progres-
sion in bladder cancer. American Journal of Pathology 2002;161:
1199–206.
20]  Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of
tumours  of the urinary system and male genital organs. Lyon: IARC;
2004.
21] Sobin LH, Gospodarowicz MK,  Wittekind C. TNM classiﬁcation of
malignant tumours. 7th ed. Weinheim: Wiley; 2009.
22] Wolff AC, Hammond ME,  Schwartz JN, Hagerty KL, Allred DC, Cote
RJ,  et al. American Society of Clinical Oncology; College of American
Pathologists. American Society of Clinical Oncology/College of Amer-
ican  Pathologists guideline recommendations for human epidermal
growth factor receptor 2 testing in breast cancer. Journal of Clinical
Oncology 2007;25:118–45.
23] Zigeuner R, Tsybrovskyy O, Ratschek M,  Rehak P, Lipsky K, Langner C.
Prognostic  impact of p63 and p53 expression in upper urinary tract
transitional cell carcinoma. Urology 2004;63:1079–83.
24]  Bernardini S, Adessi GL, Billerey C, Chezy E, Carbillet JP, Bittard
H. Immunohistochemical detection of p53 protein overexpression
versus gene sequencing in urinary bladder carcinomas. Journal of
Urology  1999;162:1496–501.
25] Tiguert R, Bianco Jr FJ, Oskanian P, Li Y, Grignon DJ, Wood Jr DP,
et  al. Structural alteration of p53 protein in patients with mus-
cle invasive bladder transitional cell carcinoma. Journal of Urology
2001;166:2155–60.
26]  Bernardini S, Billerey C, Martin M, Adessi GL, Wallerand H, Bittard H.
The  predictive value of muscularis mucosae invasion and p53 over
expression on progression of stage T1 bladder carcinoma. Journal of
Urology  2001;165:42–6.
27] Shiina H, Igawa M,  Shigeno K, Yamasaki Y, Urakami S, Yoneda T, et al.
Clinical  signiﬁcance of mdm2  and p53 expression in bladder can-
cer.  A comparison with cell proliferation and apoptosis. Oncology
1999;56:239–47.
28]  Shiina H, Igawa M,  Yagi H, Urakami S, Yoneda T, Shirakawa H, et al.
Immunohistochemistry of p53 protein in transitional-cell carcinoma
of  the bladder using an image analyzer. Oncology 1996;53:233–40.
